JEROME B ZELDIS

CIK 1433982 · Executive VP of Research & Dev · last filed 2026-01-06

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.49M

Companies

8

Total Filings

79

Lifetime Open-Market Net

-$1.48M

Filer Profile

Reported Address
8767 E. VIA DE VENTURA, SUITE 190
SCOTTSDALE, AZ 85258
Related Filers
Sorrento Therapeutics, Inc. — 5 joint filings, latest 2018-11-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PTCT Director 22,500 $66.06 $1.49M -$2.00M 15 2026-01-06
NXGLW Director 106,664 $0.01 $1.4K $106.6K 8 2025-06-27
SNGX Director $0.36 $0 4 2025-06-20
NexImmune, Inc. (NEXI) Delisted Executive VP of Research & Dev 235 $0.00 $0 $100.0K 3 2022-04-07
SOLIGENIX, INC. (SNGXW) Delisted Director 25,917 $0.01 $233 $12.8K 9 2021-09-24
Streamex Corp. (BSGM) Delisted Director 10,794 $6.35 $68.5K $10.5K 5 2020-07-15
Sorrento Therapeutics, Inc. (SRNE) Delisted See Remarks 10,000 $0.00 $5 $51.5K 4 2018-11-27
Alliqua BioMedical, Inc. (ALQA) Delisted Director 131,125 $240.7K 8 2017-07-03

Recent Filings · Page 4 of 8

79 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-05-28 Streamex Corp. (BSGM) Delisted Buy (P) +1,000 $10.5K EDGAR
2020-04-16 Streamex Corp. (BSGM) Delisted Grant (A) $0 EDGAR
2020-01-31 PTCT Grant (A) +1,650 $0 EDGAR
2019-11-19 SOLIGENIX, INC. (SNGXW) Delisted Buy (P) +2,000 $1.9K EDGAR
2019-10-31 Streamex Corp. (BSGM) Delisted Grant (A) $0 EDGAR
2019-09-23 SOLIGENIX, INC. (SNGXW) Delisted Buy (P) +4,000 $3.7K EDGAR
2019-09-10 SOLIGENIX, INC. (SNGXW) Delisted Grant (A) $0 EDGAR
2019-05-22 Streamex Corp. (BSGM) Delisted Mixed +38,235 $153.8K EDGAR
2019-04-22 SOLIGENIX, INC. (SNGXW) Delisted Buy (P) +10,000 $7.3K EDGAR
2019-01-24 PTCT Grant (A) $0 EDGAR
Showing 3140 of 79
Page 4 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.